Compare Crown Castle International Corp (CCI) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crown Castle International Corp vs TG Therapeutics Inc — how do they compare? Crown Castle International Corp trades at $79.05 (market cap $34.85B), while TG Therapeutics Inc trades at $54.84 (market cap $8.42B). The key difference: Crown Castle International Corp is far larger — about 4.1× TG Therapeutics Inc's market cap, and Crown Castle International Corp pays a 5.32% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| CCI | TGTX | |
|---|---|---|
Market Cap | $34.85B | $8.42B |
Sector | Real Estate | Health |
52-Week High | $113.91 | $59.06 |
52-Week Low | $74.92 | $26.39 |
Enterprise Value | $64.67B | $8.66B |
Dividend Yield | 5.32% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crown Castle International Corp
Crown Castle International owns and leases roughly 40,000 cell towers in the United States. It also owns more than 85,000 route miles of fiber. It leases space on its towers to wireless service providers, which install equipment on the towers to support their wireless networks. The company's fiber is primarily leased by wireless service providers to set up small-cell network infrastructure and by enterprises for their internal connection needs. Crown Castle's towers and fiber are predominantly located in the largest U.S. cities. The company has a very concentrated customer base, with more than 70% of its revenue coming from the big three U.S. mobile carriers. Crown Castle operates as a real estate investment trust.
Read more on CCI →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
